GlassScriptPhysician profile
Mohammed A Raheem
NPI 1750394805
$6,611.73
in general payments reported to CMS, 2019-2025
16 companies · $58.42 in 2025
The $58.42 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,808 · 2020: $48.15 · 2021: $102 · 2022: $592 · 2023: $376 · 2024: $627 · 2025: $58.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Education: $58.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.07 |
| Education | $58.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $4,768.65 | 2019 | |
| Merck Sharp & Dohme LLC | $607.14 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $349.40 | 2022 | |
| Pfizer INC. | $224.57 | 2023-2024 | |
| Gilead Sciences, INC. | $164.77 | 2023-2024 | |
| Daiichi Sankyo INC. | $107.42 | 2024 | Enhertu |
| Celgene Corporation | $101.04 | 2022-2024 | Pomalyst |
| G1 Therapeutics, INC. | $65.46 | 2022-2023 | Cosela |
| Tempus Ai, INC | $64.23 | 2024 | |
| Amgen INC. | $32.72 | 2025 | |
| Incyte Corporation | $31.50 | 2021-2022 | |
| Genentech USA, INC. | $22.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.41 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.73 | 2023 | |
| Cti Biopharma Corp. | $17.10 | 2023 | Vonjo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Raheem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.